- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01833468
Functional Limitations Due To The Foot Involvement In Spondyloarthritis
April 16, 2013 updated by: Vakif Gureba Training and Research Hospital
FUNCTIONAL LIMITATIONS DUE TO the FOOT INVOLVEMENT IN SPONDYLOARTHRITIS
Seronegative spondyloarthritis (SpA) is a group of rheumatic diseases Foot involvement of the SpA is common and enthesitis, erosive changes or ankylosis are the frequent lesions.
The functional status of the SpA patients are usually evaluated globally.The aim of this study is to assess specifically the foot -related functional limitations of the SpA patients.
Study Overview
Status
Completed
Conditions
Detailed Description
SpA patients who had foot pain at least for 4 weeks and those having bilateral anteroposterior and lateral feet x-rays will be included into the study.
Foot x-rays will be evaluated by a radiologist by using the spondyloarthropathy tarsal radiographic index (SpA-TRI).
The foot related functional status of the patients will be determined by the Turkish version of the Foot and Ankle Outcome Score (FAOS).
Study Type
Observational
Enrollment (Actual)
30
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
patients with SpA and foot pain
Description
Inclusion Criteria:
- SpA patients who had foot pain at least for 4 weeks
- Those having bilateral anteroposterior and lateral feet x-rays will be included into the study
Exclusion Criteria:
- Patients who had flatfoot
- Previous foot surgery
- Any other disorder unrelated to the SpA will be excluded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The foot-related functional status of SpA patients
Time Frame: 1 month
|
The foot related functional status of the subjects will be measured with Foot Ankle Outcome Score (FAOS)
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: nihal ozaras, ass.prof, Bezmialem Vakif University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (ACTUAL)
April 1, 2013
Study Completion (ACTUAL)
April 1, 2013
Study Registration Dates
First Submitted
April 8, 2013
First Submitted That Met QC Criteria
April 12, 2013
First Posted (ESTIMATE)
April 16, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
April 17, 2013
Last Update Submitted That Met QC Criteria
April 16, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Foot-SpA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriatic Arthritis
-
AmgenRecruitingActive Juvenile Psoriatic ArthritisSpain, France, Greece, Italy, United Kingdom, Austria, Germany, Netherlands, Lithuania, Romania, South Africa, Portugal, Belgium, Turkey (Türkiye), Poland
-
Universitätsklinikum Hamburg-EppendorfBristol-Myers Squibb; Eli Lilly and Company; UCB Pharma; Merck Sharp & Dohme LLC; AbbVi... and other collaboratorsRecruiting
-
Dr. Schär AG / SPAASST Gaetano Pini-CTOCompleted
-
Bristol-Myers SquibbCompletedPsoriatic Arthritis (PsA)Germany
-
Pope Research CorporationAmgenWithdrawn
-
Medical College of WisconsinNot yet recruitingPsoriatic Arthritis (PsA)United States
-
Sun Pharmaceutical Industries LimitedActive, not recruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Germany, India, Japan, Poland, Spain, South Korea
-
AbbVieActive, not recruitingPsoriatic Arthritis (PsA)United States, Australia, Belgium, Canada, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Puerto Rico, Singapore, South Africa, Spain, Sweden, United Kingdom, Argentina, Brazil, Denmark, P... and more
-
Chao JiEnrolling by invitationSubclinical Psoriatic ArthritisChina
-
Sun Pharmaceutical Industries LimitedCompleted